Events8th International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session S4. Small molecules as drug candidates of the event 8th International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2022
Academic Editor
author-avatarAlfredo Berzal-Herranz
Citation
Krzysztof Szafrański, Jarosław Sławiński, Anna Kawiak, Anticancer evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides, in Proceedings of 8th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2022, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2022-13280
Share
Email
Facebook
Twitter
LinkedIn

Anticancer evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides

Anna Kawiak 3
1. Department of Organic Chemistry, Medical University of Gdańsk, Poland
2. Department of Organic Chemistry, Medical University of Gdańsk
3. Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk
Abstract

During our research over biological activity of different N-aryl-4-substututed-pyridine-3-sulfonamides we have found that compound bearing N-(quinolin-8-yl) substituent possess a significant anti-tumor activity. Mechanisms of anticancer activity of N-(quinoline)sulfonamide derivatives was reported to be inhibition of NF-κB pathway. Nuclear factor NF-κB regulates expression of genes that control cell proliferation and cell survival thus it is consider as potential molecular targets for the prevention and treatment of cancer. Based on this information we decided to synthesize and evaluate series of 4-amino-N-(quinolin-8-yl)pyridine-3-sulfonamides, which contain both 8-amonoquinolin group and pyridine-3-sulfonamide scaffold.

Target compounds were obtained in multistep reaction starting from 4-hydroxypyridine, and their structure was confirmed using the spectroscopic methods: IR, 1H NMR, and elemental analysis (C, H, N), Synthesized compounds were tested using MTT assay towards their effect on growth of three human cancer cell lines: colon cancer HCT-116, breast cancer MCF-7 and cervical cancer HeLa as well as on noncancerous keratinocyte cell line HaCaT. Cell viability was measured after 72 h of incubation with tested compound in five concentration 1 – 100 μM.

All compounds show very high activity comparable to cisplatin against cancer cells lines (IC50=4-43 μM), and selectivity relative to HaCaT cells.

Keywords
sulfonamides
anticancer activity
pyridine
quinoline
Poster
sciforum-066067.pdf
Molecular docking analysis of novel thiourea derivatives of naproxen with potential anti-inflammatory activity
New N-benzenesulfonylguanidine derivatives and their selective growth inhibition of human breast cancer cell line MCF-7 and colon carcinoma HCT-116